Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Phase 3 Recruiting
380 enrolled
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
416 enrolled
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Phase 3 Recruiting
320 enrolled
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Phase 3 Recruiting
336 enrolled
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Phase 3 Recruiting
266 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Recruiting
630 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
Krascendo 2
Phase 3 Recruiting
600 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Phase 3 Recruiting
840 enrolled
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Phase 3 Recruiting
593 enrolled
eVOLVE-Meso
Phase 3 Recruiting
825 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Phase 3 Recruiting
180 enrolled
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Phase 3 Recruiting
462 enrolled
TROPION-Lung15
Phase 3 Recruiting
744 enrolled
SOHO-02
Phase 3 Recruiting
278 enrolled
RePaIr-HN
Phase 3 Recruiting
214 enrolled
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Phase 3 Recruiting
1,780 enrolled
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 Recruiting
750 enrolled
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Phase 3 Recruiting
225 enrolled
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Phase 3 Recruiting
286 enrolled
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Phase 3 Recruiting
150 enrolled
DESTINY-BTC01
Phase 3 Recruiting
620 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Phase 3 Recruiting
878 enrolled
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Phase 3 Recruiting
300 enrolled
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Phase 3 Recruiting
380 enrolled
OLYMPIA-4
Phase 3 Recruiting
216 enrolled
REZILIENT4
Phase 3 Recruiting
360 enrolled
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Phase 3 Recruiting
486 enrolled
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Phase 3 Recruiting
604 enrolled
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Phase 3 Recruiting
420 enrolled
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Phase 3 Recruiting
300 enrolled
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Phase 3 Recruiting
474 enrolled
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Phase 3 Recruiting
300 enrolled
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Phase 3 Recruiting
432 enrolled
HOTT
Phase 3 Recruiting
220 enrolled
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Phase 3 Recruiting
720 enrolled
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Phase 3 Recruiting
440 enrolled
TRITON
Phase 3 Recruiting
280 enrolled
ECLIPSE
Phase 3 Recruiting
412 enrolled
NAUTICAL
Phase 3 Recruiting
14 enrolled
TAB-2
Phase 3 Recruiting
220 enrolled
LEDANG
Phase 3 Recruiting
123 enrolled